Leerink Partnrs Issues Positive Estimate for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings of $0.14 per share for the quarter, up from their previous estimate of $0.11. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q4 2025 earnings at $0.14 EPS and FY2025 earnings at $0.84 EPS.

Several other analysts have also recently weighed in on the company. Morgan Stanley dropped their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Barclays decreased their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health has a consensus rating of “Hold” and a consensus target price of $15.00.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $12.02 on Monday. The stock has a market capitalization of $5.97 billion, a P/E ratio of 30.05, a P/E/G ratio of 2.50 and a beta of 1.49. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $9.89 and a two-hundred day moving average price of $11.42.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the transaction, the director now owns 101,459 shares of the company’s stock, valued at $1,105,903.10. This trade represents a 10.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Hillsdale Investment Management Inc. grew its position in shares of Elanco Animal Health by 2.1% in the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company’s stock valued at $524,000 after purchasing an additional 900 shares during the period. Arizona State Retirement System lifted its stake in Elanco Animal Health by 0.8% in the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company’s stock valued at $1,737,000 after acquiring an additional 1,166 shares in the last quarter. MTM Investment Management LLC lifted its stake in Elanco Animal Health by 9.3% in the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock valued at $172,000 after acquiring an additional 1,200 shares in the last quarter. Graypoint LLC lifted its stake in Elanco Animal Health by 4.9% in the 1st quarter. Graypoint LLC now owns 26,845 shares of the company’s stock valued at $282,000 after acquiring an additional 1,256 shares in the last quarter. Finally, Commerce Bank lifted its stake in Elanco Animal Health by 3.7% in the 1st quarter. Commerce Bank now owns 35,321 shares of the company’s stock valued at $371,000 after acquiring an additional 1,256 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.